3,723 results match your criteria low-risk prostate

Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.

Int J Nanomedicine 2021 12;16:2775-2787. Epub 2021 Apr 12.

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Purpose: With the advance of screening techniques, there is a growing number of low-risk or intermediate-risk prostate cancer (PCa) cases, remaining a serious threat to men's health. To obtain better efficacy, a growing interest has been attracted to develop such emerging treatments as immunotherapy and focal therapy. However, few studies offer guidance on whether and how to combine these modalities against PCa. Read More

View Article and Full-Text PDF

Zinc stable isotopes in urine as diagnostic for cancer of secretory organs.

Metallomics 2021 Apr 20. Epub 2021 Apr 20.

Department of Earth Sciences, University of Oxford, South Parks Road, UK.

Breast, prostatic and pancreatic cancers alter the zinc (Zn) metabolism. Combined analyses of urinary Zn concentrations ([Zn]) and Zn stable isotope compositions (δ66Zn) may provide a non-invasive approach for tracing malignancy-induced Zn dyshomeostasis. In this study, we measured [Zn] and δ66Zn in urine from prostate (n = 22), breast (n = 16) and from women with benign breast disease (n = 14) and compared those to age-matched healthy controls (22-49 yrs or 50 + yrs) and published data for pancreatic cancer (n = 17). Read More

View Article and Full-Text PDF

Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance.

Eur Urol Oncol 2021 Apr 21;4(2):227-234. Epub 2020 Oct 21.

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

Background: The ability of serial magnetic resonance imaging (MRI) to capture pathologic progression during active surveillance (AS) remains in question.

Objective: To determine whether changes in MRI are associated with pathologic progression for patients on AS.

Design, Setting, And Participants: From July 2007 through January 2020, we identified all patients evaluated for AS at our institution. Read More

View Article and Full-Text PDF

Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach.

Korean J Radiol 2021 Apr 1. Epub 2021 Apr 1.

Department of Radiology, Tan Tock Seng Hospital, Singapore.

MRI has become important for the detection of prostate cancer. MRI-guided biopsy is superior to conventional systematic biopsy in patients suspected with prostate cancer. MRI is also increasingly used for monitoring patients with low-risk prostate cancer during active surveillance. Read More

View Article and Full-Text PDF

Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.

PLoS One 2021 14;16(4):e0249123. Epub 2021 Apr 14.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States of America.

Purpose: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses. This study aimed to map EPIC tool to EuroQoL-5D-3L (EQ5D) to generate EQ5D health utilities.

Methods And Materials: This is a secondary analysis of a prospective, randomized non-inferiority clinical trial, conducted between 04/2006 and 12/2009 at cancer centers across the United States, Canada, and Switzerland. Read More

View Article and Full-Text PDF

Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy.

Transl Androl Urol 2021 Mar;10(3):1018-1029

Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Background: Prostate cancer (PCa) is the second lethal heterogeneous cancer among males worldwide, and approximately 20% of PCa patients following radical prostatectomy (RP) will undergo biochemical recurrence (BCR). This study is aimed to identify the immune-related gene signature that can predict BCR in localized PCa following RP.

Methods: Expression profile of genes together with clinical parameters from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus database (GEO) and the immune-related genes from the Molecular Signatures Database v4. Read More

View Article and Full-Text PDF

Focal Therapy is a viable treatment for low risk Prostate cancer.

J Endourol 2021 Apr 13. Epub 2021 Apr 13.

University of Michigan, 1259, Department of Urology, Ann Arbor, Michigan, United States;

Focal therapy (FT) is a promising alternative to definitive therapy for localized prostate cancer (PCa). Rather than simply monitoring cancer through active surveillance (AS) or risking the side effects of robotic radical prostatectomy (RP) it offers an intermediate solution. Azzouzi et al. Read More

View Article and Full-Text PDF

Focal Therapy for Low-Risk Prostate Cancer Opinion: No.

J Endourol 2021 Apr 13. Epub 2021 Apr 13.

University of Southern California Catherine and Joseph Aresty Department of Urology, 271774, Los Angeles, California, United States;

No Abstract. Read More

View Article and Full-Text PDF

Detection of clinically significant prostate cancer with F-DCFPyL PET/multiparametric MR.

Eur J Nucl Med Mol Imaging 2021 Apr 12. Epub 2021 Apr 12.

Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, M5G 2M9, Canada.

Purpose: To assess whether F-DCFPyL PET/multiparametric (mp)MR contributes to the diagnosis of clinically significant (cs) prostate cancer (PCa) compared to mpMR in patients with suspicion of PCa, or patients being considered for focal ablative therapies (FT).

Patients And Methods: This ethics review board-approved, prospective study included 55 men with suspicion of PCa and negative systematic biopsies or clinically discordant low-risk PCa (n = 21) or those being considered for FT (n = 34) who received F-DCFPyL PET/mpMR. Each modality, PET, mpMR, and PET/MR (using the PROMISE classification), was assessed independently. Read More

View Article and Full-Text PDF

Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.

Eur Urol Oncol 2021 Apr 10. Epub 2021 Apr 10.

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Background: While magnetic resonance imaging (MRI)-targeted biopsy (TBx) results in better prostate cancer (PCa) detection relative to systematic biopsy (SBx), the combination of both methods increases clinically significant PCa detection relative to either Bx method alone. However, combined Bx subjects patients to higher number of Bx cores and greater detection of clinically insignificant PCa.

Objective: To determine if prebiopsy prostate MRI can identify men who could forgo combined Bx without a substantial risk of missing clinically significant PCa (csPC). Read More

View Article and Full-Text PDF

What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study.

Prostate Cancer Prostatic Dis 2021 Apr 8. Epub 2021 Apr 8.

Department of Urology, Erasmus University Medical Centre Cancer Institute, Rotterdam, The Netherlands.

Background: The reduction of overtreatment by active surveillance (AS) is limited in patients with low-risk prostate cancer (PCa) due to high rates of patients switching to radical treatment. MRI improves biopsy accuracy and could therewith affect inclusion in or continuation of AS. We aim to assess the effect of MRI with target biopsies on the total rate of patients discontinuing AS, and in particular discontinuation due to Grade Group (GG) reclassification. Read More

View Article and Full-Text PDF

Association Between One-time Prostate-Specific Antigen (PSA) Test with Free/Total PSA and Prostate Cancer Mortality: A 30-year Prospective Cohort Study.

BJU Int 2021 Apr 3. Epub 2021 Apr 3.

Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

Objectives: To explore if there is a long-term association between baseline prostate-specific antigen (PSA), including free/total PSA ratio and long-term (30 years) risk for prostate cancer death.

Subjects And Methods: In all, 1782 men were screened for prostate cancer through PSA analysis. Some years later, frozen plasma samples were used to calculate the ratio of free-to-total PSA (f/t PSA). Read More

View Article and Full-Text PDF

Outcomes of prostate cancer screening among men using antidiabetic medication.

Sci Rep 2021 Apr 1;11(1):7363. Epub 2021 Apr 1.

Faculty of Social Sciences, University of Tampere, Tampere, Finland.

Diabetic men have decreased risk for prostate cancer (PCa) overall and lower PSA compared to non-diabetics. This may affect the outcomes of PSA-based screening. We investigated the effect of PSA-based screening at 4-year intervals on PCa incidence and mortality separately among users and non-users of antidiabetic medication with the hypothesis that screening would detect less low-grade cancer and more high-grade cancer in diabetic men. Read More

View Article and Full-Text PDF

[Risk-adapted prostate cancer screening-update 2021].

Urologe A 2021 Apr 1. Epub 2021 Apr 1.

Medizinische Fakultät, Universitätsklinikum Düsseldorf, Klinik für Urologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

Background: Prostate cancer (PCa) is the most common cancer and the second leading cause of cancer death in men in industrialized countries. There is no commonly accepted prostate cancer screening strategy. Based on the experience of various international screening studies, the German Prostate Cancer Early Detection Study Based on a Baseline PSA Value in Young Men (PROBASE) was established in 2014. Read More

View Article and Full-Text PDF

Localized and Locally Advanced Prostate Cancer: Treatment Options.

Oncology 2021 Mar 30:1-9. Epub 2021 Mar 30.

Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Background: There are many treatment options for localized and locally advanced prostate cancer with radiotherapy and surgery representing the main local therapeutic strategies.

Summary: Depending on the risk of disease recurrence, we can stratify patients into low-, intermediate- and high-risk groups, which will guide patients' treatment. For low-risk patients, active surveillance is an option. Read More

View Article and Full-Text PDF

Biparametric MRI prior to Radical Radiation Therapy for Prostate Cancer in a Caribbean Population: Implications for Risk Group Stratification and Treatment.

Radiol Imaging Cancer 2020 Jul 31;2(4):e200007. Epub 2020 Jul 31.

Departments of Clinical Medical Sciences (M.A.G., D.N.) and Paraclinical Sciences (S.M.), Faculty of Medical Sciences, Eric Williams Medical Sciences Complex, Building 39, First Floor Uriah Butler Highway, Champ Fleurs, University of the West Indies, St Augustine Campus, St Augustine, Trinidad; and Departments of Urology (A.P.R., K.S.) and Radiology (C.M.G., M.D.M., R.B.), San Fernando General Hospital, Paradise Pasture Independence Avenue, San Fernando, Trinidad.

Purpose: To assess risk-group migration and subsequent management change following biparametric MRI using a risk-stratified approach in a group of Caribbean men with prostate adenocarcinoma being offered external beam radiation therapy (EBRT).

Materials And Methods: This retrospective study assessed the biparametric MRI findings in men who opted for EBRT from January 2018 to June 2019 ( = 79; mean age, 67.9 years ± 6. Read More

View Article and Full-Text PDF

Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer.

Front Mol Biosci 2021 11;8:608369. Epub 2021 Mar 11.

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

The incidence of prostate cancer (PCa) is high and increasing worldwide. The prognosis of PCa is relatively good, but it is important to identify the patients with a high risk of biochemical recurrence (BCR) so that additional treatment could be applied. Level 3 mRNA expression and clinicopathological data were obtained from The Cancer Genome Atlas (TCGA) to serve as training data. Read More

View Article and Full-Text PDF

VMAT for prostate cancer with 6-MV and 10-MV photons: Impact of beam energy on treatment plan quality and model-based secondary cancer risk estimates.

Mol Clin Oncol 2021 May 5;14(5):89. Epub 2021 Mar 5.

Department of Medical Physics, Faculty of Medicine, University of Crete, 71003 Iraklion, Greece.

The aim of the present study was to examine the effect of the photon beam energy on the volumetric modulated arc therapy (VMAT) plan quality for prostate cancer and on the risk of secondary carcinogenesis. Separate VMAT plans with 6-MV and 10-MV photons were created for 11 low-risk patients with prostate cancer. The prescribed tumor dose was 70 Gy delivered in 28 fractions. Read More

View Article and Full-Text PDF

[68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.

Arch Ital Urol Androl 2021 Mar 18;93(1):21-25. Epub 2021 Mar 18.

Department of Urology and Renal Transplantation, Coimbra University Hospital Center, Coimbra; Faculty of Medicine, Coimbra University, Coimbra.

Objectives: Clinical approach of prostate cancer (PCa) biochemical recurrence (BCR) is an ever-changing topic. Prostate-specific membrane antigen positron emission tomography ([68Ga]Ga-PSMA-11 PET-CTPSMA PET-CT) has shown good potential in this field. The aim is to evaluate PSMA PET-CT detection rate in PCa BCR and assess its impact on clinical outcome. Read More

View Article and Full-Text PDF

Inverse Stage Migration in Radical Prostatectomy-A Sustaining Phenomenon.

Front Surg 2021 1;8:612813. Epub 2021 Mar 1.

Department of Urology, University Hospital Frankfurt, Frankfurt, Germany.

To investigate temporal trends in prostate cancer (PCa) radical prostatectomy (RP) candidates. Patients who underwent RP for PCa between January 2014 and December 2019 were identified form our institutional database. Trend analysis and logistic regression models assessed RP trends after stratification of PCa patients according to D'Amico classification and Gleason score. Read More

View Article and Full-Text PDF

High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.

Sci Rep 2021 Mar 17;11(1):6165. Epub 2021 Mar 17.

Department of Radiology, Kansai Medical University, Hirakata, 573-1010, Japan.

To compare the outcomes of localized prostate cancer treatment with high-dose-rate brachytherapy (HDR-BT) and low-dose-rate brachytherapy (LDR-BT), we examined 924 patients treated with HDR-BT + external beam radiotherapy (EBRT) and 500 patients treated with LDR-BT ± EBRT using multi-institutional retrospective data. The HDR-BT treated advanced disease with more hormonal therapy than LDR-BT. To reduce background selection bias, we performed inverse probability of treatment weighting (IPTW) analysis using propensity scores and excluded patients with T3b-4 disease/ initial prostate-specific antigen (PSA) levels > 50 ng/ml. Read More

View Article and Full-Text PDF

Characteristics and risk differences of different tumor size on localized prostate cancer: A retrospective cohort study in the SEER database.

Cancer Med 2021 Apr 16;10(8):2763-2773. Epub 2021 Mar 16.

Department of Urology, Shanghai Tenth People's Hospital,Tongji University School of Medicine, Shanghai, China.

Objective: We aimed to evaluate the role of tumor size in predicting tumor risk for localized prostate cancer (PCa) patients undergoing radical prostatectomy (RP).

Methods: Twenty-five thousand, one hundred twenty-seven men with PCa receiving RP from 2010 to 2015 were extracted from the Surveillance, Epidemiology, and End Results database. Kaplan-Meier plots and multivariable Cox regression analyses were used to illustrate overall survival (OS) according to the tumor size. Read More

View Article and Full-Text PDF

A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.

J Magn Reson Imaging 2021 Mar 14. Epub 2021 Mar 14.

Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.

Background: A definitive diagnosis of prostate cancer requires a biopsy to obtain tissue for pathologic analysis, but this is an invasive procedure and is associated with complications.

Purpose: To develop an artificial intelligence (AI)-based model (named AI-biopsy) for the early diagnosis of prostate cancer using magnetic resonance (MR) images labeled with histopathology information.

Study Type: Retrospective. Read More

View Article and Full-Text PDF

Regional Anaesthesia in Harris Platelet Syndrome for Transurethral Resection of Prostate-A Clinical Conundrum or Certitude?

Turk J Anaesthesiol Reanim 2021 Feb 5;49(1):67-69. Epub 2020 May 5.

Department of Anaesthesia and Pain Medicine, Sri Ramachandra Medical College and Research Institute, Chennai, India.

Routine use of the autoanalyzer has helped uncover the increasing incidence of thrombocytopenia. Disorders associated with macrothrombocytes with thrombocytopenia necessitate a preoperative evaluation to assess the bleeding tendencies and the need for transfusion of blood products. Harris platelet syndrome is one such disorder where macrothrombocytes with thrombocytopenia are associated with no congenital abnormalities and low risk of bleeding intraoperatively. Read More

View Article and Full-Text PDF
February 2021

Predictive model containing PI-RADS v2 score for postoperative seminal vesicle invasion among prostate cancer patients.

Transl Androl Urol 2021 Feb;10(2):584-593

Department of Urology, Peking University First Hospital, Beijing, China.

Background: Seminal vesicle invasion (SVI) is considered to be one of most adverse prognostic findings in prostate cancer, affecting the biochemical progression-free survival and disease-specific survival. Multiparametric magnetic resonance imaging (mpMRI) has shown excellent specificity in diagnosis of SVI, but with poor sensitivity. The aim of this study is to create a model that includes the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) score to predict postoperative SVI in patients without SVI on preoperative mpMRI. Read More

View Article and Full-Text PDF
February 2021

Presenting Stage and Risk Group in Men Dying of Prostate Cancer.

Curr Oncol 2020 Dec 1;27(6):547-551. Epub 2020 Dec 1.

: Prostate cancer remains the 3rd leading cause of cancer-related mortality in Canadian men, and yet screening for prostate cancer continues to be controversial because the majority of men diagnosed with prostate cancer do not die of the disease. It also remains uncertain whether treatment of cases that can be treated with curative intent alters the mortality rate. There are very few studies describing the presenting stage, risk groups, and survival after diagnosis for men dying of prostate cancer in the literature. Read More

View Article and Full-Text PDF
December 2020

Robust Machine Learning for Colorectal Cancer Risk Prediction and Stratification.

Front Big Data 2020 10;3. Epub 2020 Mar 10.

Department of Therapeutic Radiology, Yale University, New Haven, CT, United States.

While colorectal cancer (CRC) is third in prevalence and mortality among cancers in the United States, there is no effective method to screen the general public for CRC risk. In this study, to identify an effective mass screening method for CRC risk, we evaluated seven supervised machine learning algorithms: linear discriminant analysis, support vector machine, naive Bayes, decision tree, random forest, logistic regression, and artificial neural network. Models were trained and cross-tested with the National Health Interview Survey (NHIS) and the Prostate, Lung, Colorectal, Ovarian Cancer Screening (PLCO) datasets. Read More

View Article and Full-Text PDF

4Kscore diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5% to 10%: A meta-analysis.

Urol Oncol 2021 Mar 5. Epub 2021 Mar 5.

Department of Urology, Affiliated Hospital of Guilin Medical University, Guilin city, Guangxi Province, China. Electronic address:

Background: Reported 4Kscore thresholds used to differentiate between patients with and without high-grade prostate cancer (CaP) were variable. Patients with 4Kscore results <7.5% have been proven to be at low risk of carrying high-grade CaP. Read More

View Article and Full-Text PDF

Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase.

Urology 2021 Mar 4. Epub 2021 Mar 4.

Departments of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

Objective: To analyze the effect on biochemical recurrence (BCR) of omitting PLND in subsequently upgraded/upstaged patients (pNx regret). Using nomograms, patients with low to intermediate-risk prostate cancer can be selected to omit a pelvic lymph node dissection (PLND) at the time of a radical prostatectomy (RP). However, some patients will experience upgraded pathology and/or stage. Read More

View Article and Full-Text PDF

Changes in sexual function and serum testosterone levels in patients with prostate cancer after image-guided proton therapy.

J Radiat Res 2021 Mar 2. Epub 2021 Mar 2.

Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Since sexual function and testosterone levels after image-guided proton therapy (IGPT) have not yet been examined in detail, we prospectively evaluated changes before and after IGPT. Among patients treated with IGPT with or without combined androgen blockade (CAB) therapy between February 2013 and September 2014, patients who agreed to participate in the study and were followed up for >3 years after IGPT were evaluated. Serum testosterone levels were regularly measured together with prostate-specific antigen (PSA) levels before and after IGPT. Read More

View Article and Full-Text PDF